MPM Oncology Impact Management »

Bright Minds Biosciences shares owned by MPM Oncology Impact Management

Quarter-by-quarter ownership of Bright Minds Biosciences (DRUG) shares owned by MPM Oncology Impact Management from 13F filings

Historical chart of MPM Oncology Impact Management investment in Bright Minds Biosciences

Tip: Access up to 7 years of quarterly data

All positions including Bright Minds Biosciences held by MPM Oncology Impact Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Bright Minds Biosciences by MPM Oncology Impact Management

Quarter filed Position value Share count Share price at filing
2025-12-31 $18M 230k 78.04

More positions owned by MPM Oncology Impact Management

Cullinan Therapeutics Common (CGEM)
Madrigal Pharmaceuticals Common (MDGL)
Liquidia Corp Common (LQDA)
Trevi Therapeutics Common (TRVI)
Edgewise Therapeutics Common (EWTX)
Revolution Medicines Common (RVMD)
Agios Pharmaceuticals Common (AGIO)
Uniqure NV Common (QURE)
PTC Therapeutics Common (PTCT)
Syndax Pharmaceuticals Common (SNDX)
Dyne Therapeutics Common (DYN)
Tarsus Pharmaceuticals Common (TARS)
Stoke Therapeutics Common (STOK)
Alumis Common (ALMS)
Urogen Pharma Common (URGN)

View all positions for MPM Oncology Impact Management

Top funds holding Bright Minds Biosciences

Henderson Group
Cormorant Asset Management
Vivo Capital
Perceptive Advisors
Adage Capital Partners GP
BlackRock
Braidwell
MPM Oncology Impact Management
Sio Capital Management
Balyasny Asset Management
Ikarian Capital
Eventide Asset Management
Stempoint Capital
Longwood Capital Partners
State Street Corporation

View all funds holding Bright Minds Biosciences